Constitutive activation of mutated EGFR (Epidermal Growth Factor Receptor) has been associated with a number of cancers, including lung cancer, anal cancers and glioblastoma multiforme. This 3D model reveals how Iressa (Gefitinib), the first selective inhibitor of EGFR tyrosine kinase domain, binds to EGFR.
1. Yun, C. H. et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer cell 11, 217-227, doi:10.1016/j.ccr.2006.12.017 (2007).